Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The historic “prohibition” against the use of testosterone therapy in men with a history of prostate cancer is based on a model that assumes that the androgen sensitivity of prostate cancer extends throughout the range of testosterone concentrations.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen sensitivity, testosterone therapy | 2 Comments »
For a multitude of reasons, there have been obstacles to and continue to be opportunities for improving prostate cancer education and communication to and within African American communities.
Filed under: Diagnosis, Risk, Uncategorized | Leave a Comment »
The Republic of Ireland “is estimated to have one of the highest prostate cancer incidences in Europe,” but there are no clinical guidelines with respect to PSA testing. The decision whether to test or not is therefore entirely up to individual general and family practitioners (known as “GPs” in Ireland), with — presumably — some [...]
Filed under: Diagnosis, Management | Tagged: guidelines, Ireland, PSA testing | Leave a Comment »
There are several significant news reports today. Each of these will be dealt with separately on this blog as quickly as possible. The first two are given immediately above and address PSA testing by primary care physicians and the potential to predict overall survival based on initial response to hormone therapy in men with metastatic [...]
Filed under: Uncategorized | Comments Off
Here is another of those “scientific” studies that is already being spread rapidly across the Internet and other media but which is of highly dubious scientific merit. According to a report issued by HealthDay, “Men who live in countries with the highest levels of artificial light at night appear more likely to develop prostate cancer.”
Filed under: Diagnosis, Prevention, Risk | Tagged: Diagnosis, nightime artificial light, risk | 2 Comments »
There are a number of additional reports in today’s news (above and beyond the reports on risks associated with disseminated tumor cells and a new review of PSA and PCA3 testing as aids to diagnosis):
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: circulating tumor cells, CTC, focal therapy, lycopene, silibinin, unilateral | Leave a Comment »
A new review just published in BJU International provides a current expert perspective on the roles of PSA and the much newer PCA3 test in the work-up and diagnosis of a patient suspected of prostate cancer. The entire article is available on line and will be a useful resource for many support group leaders and [...]
Filed under: Diagnosis, Management, Treatment | Tagged: Diagnosis, PCA3, PSA, work-up | 2 Comments »
It has long been known that men with apparently localized prostate cancer can relapse many years after radical prostatectomy and/or other forms of treatment that appear to have been curative. A new study from researchers at the University of Washington appears to throw some more light on why this may occur.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical recurrence, disseminated tumor cells, DTC | 11 Comments »
In addition to the reports on the early stages of the RALP learning curve and quality of life outcomes post-brachtherapy, there are a large number of additional reports in today’s news:
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: Alpharadin, arginine deiminase, bladder neck stent, fiducial marker, high-dose external beam radiation, microRNA, pelvic lymph node dissection, PNLD, radium-223, vaccine therapy | Leave a Comment »
As techniques have improved over time, one would expect the quality of long-term outcomes after permanent seed bachytherapy to improve also.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, outcomes, permananet seed implantation, quality of life | Leave a Comment »
We have regularly addressed the “learning curve” for surgeons who adopt new methods to carry our radical prostatectomies. A recent publication from an Australian group provides specific and useful insight into “early” use of the da Vinci system to carry out robot-assisted laparoscopic prostatectomy (RALP).
Filed under: Management, Treatment | Tagged: learning curve, RALP, robot-assisted laparoscopic prostatectomy | 1 Comment »
With the exception of a paper on baseline erectile dysfunction in patients undergoing radical prostatectomy, today’s news reports are filled with esoterica that are likely to be of interest only to researchers and the truly obsessed patient! We have provided only very brief summaries of the articles and links to the original abstracts.
Filed under: Diagnosis, Drugs in development, Management, Prevention, Treatment, Uncategorized | Tagged: antibody, biopsy, lymph node imaging, radiotherapy | Leave a Comment »
You see the topic come up over and over again, so let’s be clear: there is no demonstrated relationship between celibacy and risk for prostate cancer, and there are historic data to back this up.
Filed under: Risk | Tagged: celibacy, risk | 4 Comments »
Erectile dysfunction (ED) is a common medical problem with significant impact on quality of life. The existence of some degree of ED in patients with prostate cancer prior to treatment clearly has potential effects on outcomes of different treatments. Researchers at the Martini Clinic in Hamburg, Germany have now reported on baseline erectile function in [...]
Filed under: Living with Prostate Cancer, Management | Tagged: baseline, ED, erectile dysfuntion, preoperative | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site